Autres langues Curasight A/S

Actions

CURAS

DK0061295797

Cours en clôture NORDIC GROWTH MARKET Autres places de cotation 00:00:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
9,96 ^DKK	+0,20%		+9,45%	-43,89%

16/04	Curasight A/S annonce l'approbation d'une demande d'essai clinique (CTA) pour un essai de phase 2 avec uTRACE chez des patients atteints de cancer de la prostate	CI
12/04	Curasight A/S annonce des changements au sein de son conseil d'administration	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioStock: Curasight gets green light from EMA in phase II prostate cancer trial	22/04
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients	16/04
Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	16/04
Curasight announces change in the Board of Directors	12/04
Curasight A/S Announces Board Changes	12/04
BioStock: Curasight cancels rights issue and evaluates alternative financing	13/03
Curasight not to proceed with rights issue; evaluating alternative financing opportunities	11/03
Notice of Annual General Meeting 2024	06/03
The subscription period in Curasight's rights issue begins today	23/02
Curasight publishes information memorandum in connection with forthcoming rights issue	22/02
Annual Report for the fiscal year 2023	22/02
Year-end report October - December 2023	22/02
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise	19/02
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	13/02
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	13/02
Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company	13/02
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	13/02
BioStock: Curasight gets first milestone payment from Curium	02/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Curasight A/S

Actions

CURAS

DK0061295797

Autres langues

Filtres